cis-4-fluorocyclohexanol | 917771-50-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: cis-4-fluorocyclohexanol
• 英文别名: 4-fluorocyclohexanol
• CAS: 917771-50-7
• 化学式: C₆H₁₁FO
• 分子量: 118.151
• InChiKey: QINUPKIQEIKVOV-OLQVQODUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.26
• 重原子数：
  8.0
• 可旋转键数：
  0.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.23
• 氢给体数：
  1.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  cis-4-fluorocyclohexanol 在 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以71%的产率得到4-氟环己酮
  参考文献：
  名称：

  Discovery of Novel, Potent Benzamide Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Exhibiting Oral Activity in an Enzyme Inhibition ex Vivo Model^▽

  摘要：

  We report the discovery of potent benzamide inhibitors of 11beta-hydroxysteroid dehydrogenase (11beta-HSD1). The optimization and correlation of in vitro and in vivo metabolic stability will be described. Through modifications to our initial lead 2, we discovered pyridyl compound 13. This compound has a favorable pharmacokinetic profile across three species and showed a dose-dependent decrease in adipose 11beta-HSD1 activity in a monkey ex vivo pharmacodynamic model.

  DOI：

  10.1021/jm800310g
• 作为产物：
  描述：

  (1s,4s)-4-fluorocyclohexyl benzoate 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 5.0h， 以93%的产率得到cis-4-fluorocyclohexanol
  参考文献：
  名称：

  Discovery of Novel, Potent Benzamide Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Exhibiting Oral Activity in an Enzyme Inhibition ex Vivo Model^▽

  摘要：

  We report the discovery of potent benzamide inhibitors of 11beta-hydroxysteroid dehydrogenase (11beta-HSD1). The optimization and correlation of in vitro and in vivo metabolic stability will be described. Through modifications to our initial lead 2, we discovered pyridyl compound 13. This compound has a favorable pharmacokinetic profile across three species and showed a dose-dependent decrease in adipose 11beta-HSD1 activity in a monkey ex vivo pharmacodynamic model.

  DOI：

  10.1021/jm800310g

文献信息

• Synthesis of Fluorinated Cycloalkyl N-Phenylcarbamates and Their Microbial Defluorination/Oxygenation by Beauveria bassiana
  作者：Günter Haufe、Sylke Pietz、Dörthe Wölker、Roland Fröhlich

  DOI：10.1002/ejoc.200200648

  日期：2003.6

  fungus Beauveria bassiana predominantly in the 4-position relative to the electron-rich substituent. In cases involving fluorinated methylene groups potentially capable of hydroxylation, however, defluorination and formation of a ketone was observed. The formation of the ketone can be explained by primary hydroxylation to form an unstable geminal fluorohydrin, which is subsequently dehydrofluorinated

  早期的研究表明，N-苯基氨基甲酸环烷基酯主要在富电子取代基的 4 位被真菌白僵菌羟基化。然而，在涉及可能能够羟基化的氟化亚甲基的情况下，观察到脱氟和酮的形成。酮的形成可以通过伯羟基化形成不稳定的孪生氟代醇来解释，其随后被脱氟化氢。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003)
• [EN] PROLINE AMIDE COMPOUNDS AND THEIR AZETIDINE ANALOGUES CARRYING A SPECIFICALLY SUBSTITUTED BENZYL RADICAL<br/>[FR] COMPOSÉS DE PROLINE AMIDE ET LEURS ANALOGUES D'AZÉTIDINE PORTANT UN RADICAL BENZYLE À SUBSTITUTION SPÉCIFIQUE
  申请人：ABBVIE DEUTSCHLAND

  公开号：WO2018175449A1

  公开（公告）日：2018-09-27

  The present invention relates to proline amide compounds and their azetidine derivatives of formula I wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of the 5-HT2C receptor, and processes for preparing such compounds and compositions.

  本发明涉及脯氨酰胺化合物及其式I的氮杂环丙烷衍生物，其中变量如索引和描述中所定义。该发明还涉及含有这类化合物的药物组合物，它们作为5-HT2C受体的调节剂，特别是激动剂或部分激动剂的用途，用于制备用于预防或治疗对5-HT2C受体调节产生反应的病症和疾病的药物，用于预防或治疗对5-HT2C受体调节产生反应的病症和疾病的方法，以及制备这类化合物和组合物的方法。
• GLYCINE TRANSPORTER INHIBITOR
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：EP3009421A1

  公开（公告）日：2016-04-20

  The present invention provides novel compounds of formula [IA] or pharmaceutically acceptable salts thereof: which are useful in the prevention or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, Parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.

  本发明提供了新型的式[IA]化合物或其药学上可接受的盐类： 可用于预防或治疗精神分裂症、阿尔茨海默病、认知障碍、痴呆症、焦虑症（例如、广泛性焦虑症、恐慌症、强迫症、社交焦虑症、创伤后应激障碍、特定恐惧症、急性应激障碍）、抑郁症、药物依赖、痉挛、震颤、疼痛、帕金森病、注意力缺陷多动障碍、双相情感障碍、饮食失调或睡眠障碍等疾病的预防或治疗。
• Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists
  作者：Yun-Jin Hu、Miguel St.-Onge、Sébastien Laliberté、Frédéric Vallée、Shujuan Jin、Leanne Bedard、Jean Labrecque、Jeffrey S. Albert

  DOI：10.1016/j.bmcl.2014.04.045

  日期：2014.7

  A series of TRPA1 antagonists is described having a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine or a 1-aryloxyisoquinoline scaffold. These compounds have high ligand efficiency and favorable physical properties and may thus serve as scaffolds for further optimization. (C) 2014 Elsevier Ltd. All rights reserved.
• PROLINE AMIDE COMPOUNDS AND THEIR AZETIDINE ANALOGUES CARRYING A SPECIFICALLY SUBSTITUTED BENZYL RADICAL
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：EP3601255A1

  公开（公告）日：2020-02-05